Novo Nordisk A/S $NVO is Birch Capital Management LLC’s 5th Largest Position

Birch Capital Management LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 14.1% during the third quarter, HoldingsChannel reports. The firm owned 158,386 shares of the company’s stock after purchasing an additional 19,628 shares during the period. Novo Nordisk A/S makes up approximately 4.5% of Birch Capital Management LLC’s holdings, making the stock its 5th biggest holding. Birch Capital Management LLC’s holdings in Novo Nordisk A/S were worth $8,789,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. True Wealth Design LLC raised its holdings in shares of Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares in the last quarter. NewSquare Capital LLC boosted its stake in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $37,000. Maseco LLP purchased a new position in Novo Nordisk A/S in the 2nd quarter worth $39,000. Finally, Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 47.3% in the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.7%

NVO opened at $59.83 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The stock has a market cap of $267.12 billion, a PE ratio of 17.39 and a beta of 0.66. The business has a 50 day moving average of $49.87 and a 200-day moving average of $55.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. oral Wegovy rollout broadens commercial reach: Novo has launched its oral GLP‑1 (the “Wegovy Pill”) across a wide pharmacy network, making it the first oral weight‑loss GLP‑1 widely available in the U.S.; that distribution scale supports faster adoption and incremental sales versus an injection‑only offering. Read More.
• Positive Sentiment: Management sees a bigger oral market long term: Novo executives now expect oral GLP‑1 pills to capture over one‑third of the GLP‑1 market by 2030, implying a larger addressable market and more diverse revenue mix than previously modeled. That raises longer‑term revenue potential and reduces single‑product concentration risk. Read More.
• Positive Sentiment: Behavioral/health spillovers bolster product narrative: Research linking GLP‑1 receptor agonists to lower household spending on alcohol and tobacco supports a broader public‑health and societal value story that can aid payer conversations and public acceptance. Read More.
• Neutral Sentiment: Unusual options activity signals trader interest but not direction: Elevated/options flows show speculative positioning or hedging ahead of catalysts (sales data, guidance, regulation); could increase volatility in the short term without indicating a definitive fundamental shift. Read More.
• Neutral Sentiment: Increased analyst and fund attention raises visibility: Coverage from Fundsmith, Zacks and healthcare ETF narratives is driving investor focus on NVO (both positive for liquidity and sentiment but mixed on valuation). Monitor earnings/sales prints and guidance for conviction. Read More.
• Negative Sentiment: Compounded GLP‑1s pose a near‑term demand and pricing risk: CEO Mike Doustdar warned up to ~1.5M U.S. patients may be using compounded (unapproved, cheaper) GLP‑1 alternatives — that substitution can blunt uptake of branded products and pressure pricing if regulators or payers don’t constrain the compounding market. Read More.
• Negative Sentiment: Analyst caution on valuation and execution: Several commentaries urge caution despite investor confidence — potential overextension in the stock, reliance on continued rapid adoption, and execution risk around pharmacy rollout and payer coverage could cap upside. Read More.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Morgan Stanley reaffirmed an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Jefferies Financial Group initiated coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating on the stock. Finally, Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $56.21.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.